SYNERGY BETWEEN TETRANDRINE AND FK506 IN PREVENTION OF DIABETES IN BB RATS

被引：4

作者：

LIEBERMAN, I

HEIL, BV

SEOW, WK

THONG, YH

机构：

[1] UNIV QUEENSLAND,MATER CHILDRENS HOSP,DEPT CHILD HLTH,IMMUNOBIOL LAB,BRISBANE,QLD 4101,AUSTRALIA

[2] UNIV QUEENSLAND,MATER CHILDRENS HOSP,DEPT DENT,BRISBANE,QLD 4101,AUSTRALIA

[3] UNIV PITTSBURGH,BIOCHEM PHARMACOL,DIV ENDOCRINOL,PITTSBURGH,PA 15213

来源：

LIFE SCIENCES | 1993年 / 53卷 / 26期

关键词：

D O I：

10.1016/0024-3205(93)90023-V

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Delayed administration of tetrandrine, a novel broad-spectrum anti-inflammatory agent, to BB rats at a dosage schedule of 20 mg kg-1 day-1 from 79 days of age reduced the cumulative incidence of diabetes from 73.1 to 41.7% (p < 0.01). Brief treatment with the potent immunosuppressive agent FK506 at a dosage schedule of 0.5 mg kg-1 day-1 from 79 days of age for 5 days had no significant effect on the cumulative incidence of diabetes (66.7%, p > 0.1). However, the combination of tetrandrine and FK506 in the afore-mentioned dosage schedules reduced the incidence of diabetes to only 3.6% (p < 0.001). These results suggest that the strong synergy between tetrandrine and FK506 may offer a safe and effective therapeutic strategy for the treatment of patients with recent onset or imminent IDDM.

引用

页码：PL453 / PL458

页数：6